Alambic Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Alambic Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-29,536	Closed	-$258K	–	293
2019 Q4	$258K	Buy	29,536 +6,632	+29%	+$35.8K	0.22%	180
2019 Q3	$76K	Sell	22,904 -15,318	-40%	-$61.3K	0.06%	276
2019 Q2	$189K	Sell	38,222 -12,400	-24%	-$65.8K	0.12%	241
2019 Q1	$314K	Sell	50,622 -30,088	-37%	-$145K	0.13%	220
2018 Q4	$272K	Buy	80,710 +48,624	+152%	+$227K	0.11%	229
2018 Q3	$209K	Sell	32,086 -76,431	-70%	-$568K	0.17%	208
2018 Q2	$831K	Buy	+108,517	New	+$1.57M	0.23%	152

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alambic Investment Management's JNCE Position: Q1 2020 in Review

Alambic Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2020, closing a stake of 29,536 shares — an estimated $258K sold.

Alambic Investment Management first reported a position in JNCE in Q2 2018 and held it in 7 quarters. The position peaked at $831K in Q2 2018. 88 funds tracked by Wall St. Rank hold JNCE as of Q1 2020.

Alambic Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Alambic Investment Management sold 29,536 Jounce Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $258K.
Alambic Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Alambic Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $831K in Q2 2018.
88 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Alambic Investment Management's 13F filing for Q1 2020, filed 11 May 2020.